The Department of Defense's Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to Specgx LLC, doing business as Mallinckrodt Pharmaceuticals, for the supply of pharmaceutical products. The contract has a ceiling value of $4,154,058.30 and a period of performance through December 9, 2029.
Under this IDC, Specgx LLC will provide the DLA, Department of Veterans Affairs (VA), Bureau of Prisons, Indian Health Service, and other federal agencies with Methylphenidate HCL Extended Release Tablets in 10mg and 20mg strengths, packaged in 100-count bottles. The contract was competitively awarded without any set-aside designations, leveraging Specgx's expertise in manufacturing and distributing controlled substances and other specialty pharmaceutical products, particularly those used in pain management and substance abuse treatment programs within the VA healthcare system. The contract includes firm-fixed prices of $47.91 per bottle for 10mg tablets and $49.35 per bottle for 20mg tablets, with estimated annual quantities of 7,091 and 9,951 bottles respectively. Manufacturing will be performed at Specgx's Hobart, NY facility, and distribution will be managed through pharmaceutical prime vendors.
Generated 3/14/25, 9:59 AM